x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Project Oncology®

Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer. Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in

science & medicine medicine

All Episodes

00:00:00

Bringing Cancer Care Home: How Subcutaneous...

Project Oncology® ·

2025/06/05

Guest: Jorge Nieva, MD As immunotherapy becomes a cornerstone for treating a growing number of solid tumors, reducing the logistical burden of in-office care is essential. Fortunately, the at-home administration of subcutaneous formulations of immunotherapy agents like atezolizumab could help transform the way we care for patients with cancer. Learn more with Dr. Jorge Nieva, Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of

en

00:00:00

Unpacking the Logistics of At-Home Subcutaneous...

Project Oncology® ·

2025/06/05

Guest: Jorge Nieva, MD Despite the promising benefits for cancer patients, the at-home administration of subcutaneous immunotherapy poses complex operational and logistical challenges, like cost, payer preferences, and patient safety. Tune in to hear Dr. Jorge Nieva discuss these key factors and considerations impacting the implementation of at-home subcutaneous cancer immunotherapy delivery. Dr. Nieva is an Associate Professor of Clinical Medicine at the University of Southern

en

00:00:00

Investigating At-Home Subcutaneous Atezolizumab for...

Project Oncology® ·

2025/06/03

Guest: Jorge Nieva, MD Can the immune checkpoint inhibitor atezolizumab be safely administered subcutaneously at home for patients with non-small cell lung cancer (NSCLC)? That’s the exact question an ongoing study is seeking to answer, and here to discuss the study’s objective, design, and potential implications for home-based subcutaneous cancer therapies is Dr. Jorge Nivea. He’s an Associate Professor of Clinical Medicine at the University of Southern California’s Keck School of

en

00:00:00

Evaluating Dato-DXd for EGFR-Mutated Advanced NSCLC:...

Project Oncology® ·

2025/05/30

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile

en

00:00:00

Sacituzumab Govitecan for mTNBC: A Review of...

Project Oncology® ·

2025/01/07

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Paolo Tarantino, MD Sacituzumab govitecan is a TROP-2 antibody drug conjugate approved for patients with metastatic triple-negative breast cancer (mTNBC) based on findings from the ASCENT study. But how is this treatment approach performing in the real world? Joining Dr. Charles Turck to share a study’s findings on the real-world efficacy and safety of sacituzumab govitecan is Dr. Paolo Tarantino, medical oncologist and advanced

en

00:00:00

Mastering CAR-T Cell Therapy in R/R Large B-Cell...

Project Oncology® ·

2025/01/07

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It’s important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve patient

en

00:00:00

Targeting HER2-Mutant NSCLC with Trastuzumab...

Project Oncology® ·

2025/01/02

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That’s why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from

en

00:00:00

Preventing Adverse Events in CAR T-Cell Therapy: The...

Project Oncology® ·

2025/01/02

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it’s associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care

en

00:00:00

Treating Second-Line NSCLC: The Efficacy of ADCs...

Project Oncology® ·

2024/12/31

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it’s important to identify biomarkers that can predict a patient’s response to therapy. That’s why the phase 1b TROPION-LUNG02 trial examined the effectiveness

en

00:00:00

Dato-DxD for NSCLC: A Review of Final Overall...

Project Oncology® ·

2024/12/23

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That’s why there’s interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share

en

00:00:00

Analyzing Dato-DXd for Non-Squamous NSCLC with Brain...

Project Oncology® ·

2024/12/23

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That’s why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.

en

00:00:00

Evaluating Valemetostat and Dato-DXd for NSCLC: An...

Project Oncology® ·

2024/12/23

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that’s demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk

en

00:00:00

Treating NSCLC with Durvalumab, Chemotherapy, and...

Project Oncology® ·

2024/12/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological

en

00:00:00

Understanding Heparin Resistance: Underlying...

Project Oncology® ·

2024/12/16

Guest: Cheryl Maier MD, PhD Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who spoke about this topic at the 2024 American Society of Hematology Annual Meeting, to learn more about testing methods, the role of antithrombin, and alternative treatments, like direct thrombin inhibitors. Dr. Maier is an Assistant Professor in the Department of Pathology and Laboratory Medicine at

en

00:00:00

The Future of ITP Care: Exploring New Treatments

Project Oncology® ·

2024/12/16

Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children’s Hospital of Philadelphia, presented on this topic at the 2024 American

en

00:00:00

The Future of ITP Care: Exploring New Treatments

Project Oncology® ·

2024/12/16

Guest: Michele Lambert, MD, MSTR New treatments are on the horizon for patients with immune thrombocytopenia (ITP). Dr. Michele Lambert shares insights on how BTK inhibitors and immune-targeting drugs aim to address the root causes of ITP and offer more personalized care for patients. Dr. Lambert, the Medical Director of the Special Coagulation Laboratory and a physician in the Division of Hematology at Children’s Hospital of Philadelphia, presented on this topic at the 2024 American

en

00:00:00

Understanding iMCD Through RNA Sequencing

Project Oncology® ·

2024/12/16

Guest: Michael Gonzalez, PhD, MSc New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has the potential to improve both diagnosis and treatment. Join Dr. Michael Gonzalez as he dives in on his recent findings, which he spoke about at the 2024 American Society of Hematology Annual Meeting. Dr. Gonzalez is the Associate Director of Basic and Translational Research at the University of

en

00:00:00

Understanding iMCD Through RNA Sequencing

Project Oncology® ·

2024/12/16

Guest: Michael Gonzalez, PhD, MSc New research on the molecular mechanisms behind idiopathic multicentric Castleman disease (iMCD) through gene expression analysis of lymph node tissue has the potential to improve both diagnosis and treatment. Join Dr. Michael Gonzalez as he dives in on his recent findings, which he spoke about at the 2024 American Society of Hematology Annual Meeting. Dr. Gonzalez is the Associate Director of Basic and Translational Research at the University of

en

00:00:00

Understanding Heparin Resistance: Underlying...

Project Oncology® ·

2024/12/16

Guest: Cheryl Maier MD, PhD Heparin resistance occurs when patients don’t respond to anticoagulation as expected, even with what seems like the appropriate dose. Join Dr. Cheryl Maier, who spoke about this topic at the 2024 American Society of Hematology Annual Meeting, to learn more about testing methods, the role of antithrombin, and alternative treatments, like direct thrombin inhibitors. Dr. Maier is an Assistant Professor in the Department of Pathology and Laboratory Medicine at

en

00:00:00

Diagnosing Castleman Disease: Key Considerations

Project Oncology® ·

2024/12/10

Guest: Mateo Bustamante Idiopathic multicentric Castleman disease (iMCD) is a rare, life-threatening condition. Early diagnosis through excisional biopsies is key for speeding up treatment and improve patient outcomes. Learn more with Mateo Bustamante, a Senior Clinical Data Analyst at the Center for Cytokine Storm Treatment and Laboratory at University of Pennsylvania’s Perelman School of Medicine.

en

146 results

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe